A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial.

Cesar A Santa-MariaAditya BardiaAmanda L BlackfordClaire SnyderRoisin M ConnollyJohn H FettingDaniel F HayesStacie C JeterRobert S MillerAnne NguyenKatie QuinlanGary L RosnerShannon SlaterAnna Maria StornioloAntonio C WolffJane ZorziNora Lynn HenryVered Stearns

Published in: Breast cancer research and treatment (2018)

Compared to historical controls, zoledronic acid administered concomitantly with adjuvant AIs was associated with a reduced incidence of AIMSS. A randomized controlled trial is required to confirm these findings.

Keyphrases

phase ii study
open label
early stage
locally advanced
phase iii
clinical trial
study protocol
risk factors
phase ii
squamous cell carcinoma
radiation therapy
sleep quality
physical activity